Decitabine in Treating Patients With Myelofibrosis
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well decitabine works in treating
patients with myelofibrosis, a cancer of the blood system associated with fibrosis (scar
tissue) in the bone marrow that is advanced and for which there is no standard therapy.
Decitabine may block the actions of some proteins that are responsible for turning certain
genes off in various cancers including myelofibrosis.